Hims & Hers Health is trading at €29.90 (-4.41%) today amid regulatory and market pressures: - The FDA removed semaglutide and tirzepatide from the drug shortage list on July 12, 2026, ending bulk compounding exceptions and threatening a key segment of the company's GLP-1 portfolio. - Investors are also grappling with fresh regulatory jitters after FDA staff raised safety concerns about several peptides ahead of a pivotal late-July advisory meeting. - Bank of America also flagged high Wegovy subscriber churn as a threat to second-half earnings goals on July 10, 2026.